Table 2.
Characteristics | RT alone | ICI alone | RT + ICI | p value |
---|---|---|---|---|
Number of patients | 29 | 23 | 30 | |
Thoracic RTa | ||||
Prescription dose (Gy) | 61.2 (45–72) | NA | 63 (52.5–66.6) | .57 |
Lung V20 (% total lung) | 28 (17–41) | NA | 24 (14–37) | .03 |
Mean lung dose (Gy) | 16.1 (9.6–21.7) | NA | 13.5 (8.6–18.9) | .02 |
ICI type (%) | NA | .01 | ||
Nivolumab | NA | 16 (70) | 13 (43) | |
Pembrolizumab | NA | 3 (13) | 3 (10) | |
Ipilimumab‐Nivolumab | NA | 4 (17) | 3 (10) | |
Durvalumab | NA | 0 | 11 (37) | |
Interval between RT and ICI, mo | NA | NA | 4.5 (0.4–48.1) | NA |
Other treatments, n (%) | ||||
Chemotherapy | 15 (65) | 28 (97) | 29 (97) | .001 |
Thoracic surgery | 4 (17) | 8 (28) | 6 (20) | .67 |
Time to pneumonitis onset, moa | 3.1 (0.4–12.0) | 2.7 (0.1–17.5) | 1.2 (0.1–34.3) | .12 |
Pneumonitis grade (%) | .59 | |||
1 | 0 | 2 (9) | 1 (3) | |
2 | 19 (66) | 12 (52) | 19 (63) | |
3 | 9 (31) | 6 (26) | 7 (23) | |
4 | 1 (3) | 3 (13) | 3 (10) |
Continuous variables are presented as median (range).
Abbreviations: ICI, immune checkpoint inhibitor; RT, radiotherapy; V20, volume of the lung receiving 20 Gy or higher.